Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis

Language
en
Document Type
Article
Issue Date
2023-03-29
First published
2020-10-01
Issue Year
2020
Authors
Lechner, Kristina S.
Neurath, Markus F.
Weigmann, Benno
Editor
Publisher
Springer Berlin Heidelberg
Abstract

ITK (IL-2-inducible tyrosine kinase) belongs to the Tec family kinases and is mainly expressed in T cells. It is involved in TCR signalling events driving processes like T cell development as well as Th2, Th9 and Th17 responses thereby controlling the expression of pro-inflammatory cytokines. Studies have shown that ITK is involved in the pathogenesis of autoimmune diseases as well as in carcinogenesis. The loss of ITK or its activity either by mutation or by the use of inhibitors led to a beneficial outcome in experimental models of asthma, inflammatory bowel disease and multiple sclerosis among others. In humans, biallelic mutations in the ITK gene locus result in a monogenetic disorder leading to T cell dysfunction; in consequence, mainly EBV infections can lead to severe immune dysregulation evident by lymphoproliferation, lymphoma and hemophagocytic lymphohistiocytosis. Furthermore, patients who suffer from angioimmunoblastic T cell lymphoma have been found to express significantly more ITK. These findings put ITK in the strong focus as a target for drug development.

Journal Title
Journal of Molecular Medicine
Volume
98
Issue
10
Citation
Journal of Molecular Medicine 98.10 (2020): 1385–1395. <https://link.springer.com/article/10.1007/s00109-020-01958-z>
Zugehörige ORCIDs